In this group, 92/116 (79.3%) women with breast cancer and a MS of ≥40 tested positive for a BRCA1/2 PV (BRCA1 (n = 67) or BRCA2 (n = 25)). This evidence concerns the gene BRCA1 and breast carcinoma.